Temferon™:
Hematopoietic stem cell-based single treatment for solid tumors

We adapted an autologous ex-vivo cell therapy method, using the well-established lentiviral vector,to load the patient’s own TEMs precursors, that are hematopoietic stem and progenitor cells (HSPCs), with an immunotherapeutic transgene sequence. By subsequently re-introducing these modified cells into the patient, we seek to take advantage of the self-renewing and multi-differentiation nature of HSPCs to enable durable and potentially long-term effects following a one-time treatment.

HSPCs are self-renewing cells capable of differentiating into all types of blood cell. HSPCs can be obtained directly from the bone marrow or from the patient’s peripheral blood with the use of a mobilizing agent. By using  HSPCs, we create a biological reservoir of TEMs loaded with the therapeutic, with the potential to provide enduring surveillance against future relapses or metastases.